While both anti-PD1 and CTLA4 treatments showed certain degrees of success in reducing tumor growth, we demonstrated that in a pre-treatment setting, HDAC6i improves anti-tumor responses when combined with anti-PD1. Here, RPL17 is linked to neoplasm.